Dr. Paul William Thompson is a PhD translational/clinical scientist and has worked in industry for more than 20 years, leading projects in target identification through to Phase 2 in many therapeutic areas, particularly neurological disorders. During his time at Mission Therapeutics, Dr. Thompson served as VP of clinical development before becoming chief scientific officer in 2H in 2020. He has been responsible for identifying, developing and transitioning to clinic USP30 inhibitors, one of which, MTX652, completed phase I studies in 2023. He currently leads the investigation of CNS USP30 inhibitor MTX325 for Parkinson’s disease, which transitions to clinic in 2024, following successful publication of key target validation data together with Harvard Medical School and Cambridge University. Prior to Mission Therapeutics, Dr. Thompson held positions as clinical science director at Ono Pharma and director of discovery medicine neurology at GSK.